BETRF
BetterLife Pharma Inc.
OTC Markets OTCQBUSDEQUITY
Healthcare
DELAYED
Last price
0.22
▼ 0.02 (9.35%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
0.22
Prev close
0.25
Day high
0.24
Day low
0.22
Volume
23.50K
Market cap
$36.77M
P/E (TTM)
—
52W range
0.03 – 0.33
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
52.60M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 5, 26 | Sangha (Steven) 10% Security Holder of Issuer |
— | 1.00M | — | Direct |
| Jun 23, 26 | Doroudian (Ahmad) Director of Issuer |
BUY | 50.00K | $3.00K | Direct |
| Jun 22, 26 | Doroudian (Ahmad) Director of Issuer |
BUY | 50.00K | $2.50K | Direct |
| Jun 19, 26 | Drysdale (Douglas Lee) Director of Issuer |
— | 100.00K | — | Direct |
| Jun 5, 26 | Sangha (Steven) 10% Security Holder of Issuer |
BUY | 52.00K | $2.24K | Direct |
| Jun 4, 26 | Sangha (Steven) 10% Security Holder of Issuer |
BUY | 229.00K | $9.85K | Direct |
| Jun 1, 26 | Sangha (Steven) 10% Security Holder of Issuer |
BUY | 121.00K | $5.20K | Direct |
| May 29, 26 | Sangha (Steven) 10% Security Holder of Issuer |
BUY | 126.00K | $5.42K | Direct |
| May 28, 26 | Sangha (Steven) 10% Security Holder of Issuer |
BUY | 127.00K | $5.59K | Direct |
| May 27, 26 | Sangha (Steven) 10% Security Holder of Issuer |
BUY | 327.00K | $14.06K | Direct |
| May 27, 26 | Sangha (Steven) 10% Security Holder of Issuer |
BUY | 2.00K | $86 | Direct |
| May 26, 26 | Sangha (Steven) 10% Security Holder of Issuer |
BUY | 15.00K | $645 | Direct |
| May 25, 26 | Sangha (Steven) 10% Security Holder of Issuer |
BUY | 4.00K | $172 | Direct |
| May 25, 26 | Sangha (Steven) 10% Security Holder of Issuer |
SELL | 4.22M | $181.54K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Andr� (Beaudry) |
Director of Issuer | 411.55K | Acquisition or disposition in the public market |
Doroudian (Ahmad) |
Director of Issuer | 15.63M | Acquisition or disposition in the public market |
Drysdale (Douglas Lee) |
Director of Issuer | 1.61M | Acquisition or disposition under a prospectus exemption |
Pullen (Ralph Anthony) |
Director of Issuer | — | Acquisition or disposition in the public market |
Sangha (Steven) |
10% Security Holder of Issuer | 26.51M | Exercise of warrants |
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Fundamentals
Market cap$36.77M
Enterprise value$40.26M
Revenue (TTM)—
Gross profit—
EBITDA—
Net income$-1.89M
EPS (TTM)$-0.01
Free cash flow$-685.95K
Total cash$28.58K
Total debt$959.40K
Book value / share$-0.04
Shares outstanding164.89M
Float106.71M
Short % of float—
Dividend yield—
Beta (5Y)0.22
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity—
Return on assets-500.55%
Debt / equity—
Current ratio0.04
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | — | — |
| Research & development | $85.67K | $424.34K | $570.95K | $2.68M | — | -79.8% |
| Selling, general & admin | $1.72M | $4.30M | $2.64M | $6.56M | — | -59.9% |
| Total operating expense | $1.81M | $4.72M | $3.21M | $9.26M | — | -61.7% |
| Operating income | -$1.81M | -$4.72M | -$3.21M | -$9.26M | — | +61.7% |
| Net interest income | -$262.37K | $439.36K | -$84.95K | -$91.09K | — | -159.7% |
| Pre-tax income | -$1.51M | -$3.62M | -$2.90M | -$9.37M | — | +58.2% |
| Tax provision | — | — | $0 | $0 | $166.67K | — |
| Net income | -$1.50M | -$3.52M | -$2.89M | -$9.02M | — | +57.5% |
| Net income to common | -$1.50M | -$3.52M | -$2.89M | -$9.02M | — | +57.5% |
| Basic EPS | -0.01 | -0.03 | -0.03 | -0.10 | — | +66.7% |
| Diluted EPS | -0.01 | -0.03 | -0.03 | -0.10 | — | +66.7% |
| EBIT | -$1.28M | -$3.30M | -$2.85M | -$9.31M | — | +61.2% |
| EBITDA | -$1.28M | -$3.30M | -$2.85M | -$9.29M | — | +61.2% |
| Basic shares | 145.88M | 123.87M | 109.29M | 86.56M | — | +17.8% |
| Diluted shares | 145.88M | 123.87M | 109.29M | 86.56M | — | +17.8% |
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $12.57K | $8.18K | $37.38K | $8.31K | — | +53.7% |
| Cash & short-term investments | $12.57K | $8.18K | $37.38K | $8.31K | — | +53.7% |
| Accounts receivable | $2.86K | $11.64K | $39.54K | $17.20K | — | -75.5% |
| Total current assets | $219.90K | $224.96K | $324.75K | $74.73K | — | -2.2% |
| Property, plant & equipment | — | $0 | $0 | $0 | $18.43K | — |
| Goodwill & intangibles | — | — | — | $0 | $0 | — |
| Total assets | $219.90K | $224.96K | $324.75K | $74.73K | — | -2.2% |
| Total current liabilities | $6.68M | $7.54M | $7.35M | $7.15M | — | -11.4% |
| Current debt | $785.03K | $870.61K | $245.23K | $80.00K | — | -9.8% |
| Long-term debt | $27.17K | $49.12K | $82.50K | — | $34.56K | -44.7% |
| Total debt | $1.23M | $1.30M | $1.47M | $1.19M | — | -5.9% |
| Total liabilities | $6.71M | $7.59M | $8.02M | $7.61M | — | -11.6% |
| Retained earnings | -$120.09M | -$118.60M | -$115.08M | -$112.19M | — | -1.3% |
| Shareholder equity | -$9.78M | -$10.68M | -$10.81M | -$10.73M | — | +8.4% |
| Working capital | -$6.46M | -$7.31M | -$7.02M | -$7.07M | — | +11.7% |
| Net tangible assets | -$9.78M | -$10.68M | -$10.81M | -$10.73M | — | +8.4% |
| Shares issued | 151.90M | 129.57M | 115.83M | 90.10M | — | +17.2% |
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$1.51M | -$3.62M | -$2.90M | -$9.37M | — | +58.2% |
| Depreciation & amortisation | — | $0 | $0 | $18.43K | $18.44K | — |
| Stock-based compensation | $169.75K | $2.05M | $500.26K | $951.07K | — | -91.7% |
| Change in working capital | $1.21M | $752.87K | $321.61K | $3.43M | — | +61.1% |
| Operating cash flow | -$625.46K | -$2.02M | -$2.47M | -$1.50M | — | +69.1% |
| Investing cash flow | — | — | — | $0 | $0 | — |
| Financing cash flow | $629.26K | $1.99M | $2.50M | $1.34M | — | -68.4% |
| Free cash flow | -$625.46K | -$2.02M | -$2.47M | -$1.50M | — | +69.1% |
| End cash position | $12.57K | $8.18K | $37.38K | $8.31K | — | +53.7% |
| Line item | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $21.50K | $58.49K | $11.98K | $1.58K | $13.62K | -63.2% |
| Selling, general & admin | $539.89K | $378.51K | $377.24K | $510.05K | $457.12K | +42.6% |
| Total operating expense | $561.39K | $437.01K | $389.21K | $511.63K | $470.75K | +28.5% |
| Operating income | -$561.39K | -$437.01K | -$389.21K | -$511.63K | -$470.75K | -28.5% |
| Net interest income | -$29.80K | -$101.92K | -$35.76K | -$47.58K | -$77.10K | +70.8% |
| Pre-tax income | -$612.62K | -$381.62K | -$420.13K | -$504.11K | -$207.05K | -60.5% |
| Net income | -$609.26K | -$380.55K | -$409.01K | -$494.48K | -$211.45K | -60.1% |
| Net income to common | -$609.26K | -$380.55K | -$409.01K | -$494.48K | -$211.45K | -60.1% |
| Basic EPS | 0.00 | — | 0.00 | -0.00 | 0.00 | — |
| Diluted EPS | 0.00 | — | 0.00 | -0.00 | 0.00 | — |
| EBIT | -$582.83K | -$310.13K | -$384.37K | -$456.53K | -$129.95K | -87.9% |
| EBITDA | -$582.83K | -$310.13K | -$384.37K | -$456.53K | -$129.95K | -87.9% |
| Basic shares | 154.43M | — | 151.86M | 149.71M | 130.11M | — |
| Diluted shares | 154.43M | — | 151.86M | 149.71M | 130.11M | — |
| Line item | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $28.58K | $12.57K | $7.96K | $22.16K | $19.00K | — | +127.3% |
| Cash & short-term investments | $28.58K | $12.57K | $7.96K | $22.16K | $19.00K | — | +127.3% |
| Accounts receivable | $7.97K | $2.86K | $11.61K | $9.20K | $8.20K | — | +179.2% |
| Total current assets | $242.43K | $219.90K | $291.13K | $229.34K | $231.86K | — | +10.2% |
| Property, plant & equipment | — | — | — | — | — | $0 | — |
| Total assets | $242.43K | $219.90K | $291.13K | $229.34K | $231.86K | — | +10.2% |
| Total current liabilities | $6.65M | $6.68M | $6.36M | $5.99M | $6.26M | — | -0.4% |
| Current debt | $589.83K | $785.03K | $563.68K | $589.73K | $870.43K | — | -24.9% |
| Long-term debt | $27.68K | $27.17K | $95.95K | $53.61K | $51.28K | — | +1.9% |
| Total debt | $1.04M | $1.23M | $1.04M | $1.03M | $1.30M | — | -15.4% |
| Total liabilities | $6.68M | $6.71M | $6.46M | $6.04M | $6.32M | — | -0.4% |
| Retained earnings | -$120.70M | -$120.09M | -$119.71M | -$119.30M | -$118.81M | — | -0.5% |
| Shareholder equity | -$9.73M | -$9.78M | -$9.46M | -$9.12M | -$9.40M | — | +0.6% |
| Working capital | -$6.41M | -$6.46M | -$6.07M | -$5.76M | -$6.03M | — | +0.8% |
| Net tangible assets | -$9.73M | -$9.78M | -$9.46M | -$9.12M | -$9.40M | — | +0.6% |
| Shares issued | 161.79M | 151.90M | 151.90M | 151.84M | 145.37M | — | +6.5% |
| Line item | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$612.62K | -$381.62K | -$419.65K | -$504.59K | -$207.05K | -60.5% |
| Stock-based compensation | $152.93K | $9.24K | $57.68K | $38.69K | $64.14K | +1,555.1% |
| Change in working capital | $168.12K | $50.29K | $340.97K | $397.36K | $424.06K | +234.3% |
| Operating cash flow | -$239.23K | -$427.03K | -$11.87K | -$172.31K | -$14.24K | +44.0% |
| Financing cash flow | $255.06K | $431.02K | -$1.76K | $175.00K | $25.00K | -40.8% |
| Free cash flow | -$239.23K | -$427.03K | -$11.87K | -$172.31K | -$14.24K | +44.0% |
| End cash position | $28.58K | $12.57K | $7.96K | $22.16K | $19.00K | +127.3% |
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders32.49%
Held by institutions0.00%
Institutions holding0
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
—
—
SMA 20
—
—
SMA 50
—
—
SMA 100
—
—
SMA 200
—
—
EMA 12
—
—
EMA 26
—
—
EMA 50
—
—
RSI (14)
—
—
MACD (12,26,9)
—
Hist —
ATR (14)
—
—
Realised vol 30D
—
Annualised
Bollinger upper
—
20, 2σ
Bollinger lower
—
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateJun 26, 2020
Last split1:10
Split dateJun 26, 2020
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-08-05
Corporate Changes & Voting Matters
6-K · 2026-06-26
Corporate Changes & Voting Matters
6-K · 2026-06-25
Periodic Financial Reports
20-F · 2026-06-01
Corporate Changes & Voting Matters
6-K · 2026-04-13
Corporate Changes & Voting Matters
6-K · 2025-09-29
Corporate Changes & Voting Matters
6-K · 2025-07-28
Corporate Changes & Voting Matters
6-K · 2025-06-27
Headlines
BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer
TMX Newsfile · 3d ago
BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism
TMX Newsfile · 40d ago
BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee
TMX Newsfile · 44d ago
BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1
TMX Newsfile · 47d ago
BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1
TMX Newsfile · 58d ago
BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing
TMX Newsfile · 61d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.